Feedback / Questions
BMS-986326 - BMS-Bain Capital Immunology NewCo
lomedeucitinib (BMS-986322) - BMS-Bain Capital Immunology NewCo
afimetoran (BMS-986256) - BMS-Bain Capital Immunology NewCo
https://www.theglobeandmail.com/investing/markets/stocks/BMY/pressreleases/33693126/bristol-myers-squibb-and-bain-capital-create-new-company-dedicated-to-developing-innovative-immunology-therapies-that-address-the-unmet-medical-needs-of-patients/
Jul 29, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next